IRIS - Res&Arch Institutional Research Information System - Research & Archive

GROTTELLI, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 704
EU - Europa 496
AS - Asia 160
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 2
Totale 1.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 704
IE - Irlanda 177
IT - Italia 97
UA - Ucraina 87
HK - Hong Kong 66
VN - Vietnam 59
FI - Finlandia 25
DE - Germania 22
RO - Romania 22
CN - Cina 19
RU - Federazione Russa 17
BE - Belgio 12
GB - Regno Unito 9
FR - Francia 8
TR - Turchia 6
SE - Svezia 5
EU - Europa 4
NL - Olanda 4
AT - Austria 3
CH - Svizzera 3
CL - Cile 2
JP - Giappone 2
KR - Corea 2
LB - Libano 2
SG - Singapore 2
UZ - Uzbekistan 2
BG - Bulgaria 1
GR - Grecia 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
Totale 1.366
Salva come PNG Salva come JPEG
Città #
Chandler 196
Dublin 177
Hong Kong 66
San Mateo 64
Dong Ket 59
Jacksonville 47
Perugia 43
Ann Arbor 31
Medford 31
Princeton 31
Altamura 26
Wilmington 24
Lawrence 23
Bucharest 20
Andover 18
Falls Church 18
Beijing 14
Brussels 12
Fremont 11
Ashburn 7
Des Moines 6
Izmir 6
Norwalk 6
Redmond 6
Chicago 5
Redwood City 5
Saint Petersburg 5
San Paolo di Civitate 5
Dearborn 4
Helsinki 4
Montefalco 4
Frankfurt Am Main 3
Harbin 3
Los Angeles 3
Woodbridge 3
Assisi 2
Boardman 2
Den Haag 2
Gualtieri 2
New York 2
San Diego 2
Urbino 2
Amsterdam 1
Ansan-si 1
Auxvasse 1
Bratislava 1
Castiglione Del Lago 1
Fairfax 1
Fairfield 1
Groningen 1
Kiev 1
La Canada Flintridge 1
Moscow 1
Nagold 1
Padova 1
Philadelphia 1
Rome 1
Saint Louis 1
Seoul 1
Timisoara 1
Vienna 1
Zevio 1
Totale 1.020
Salva come PNG Salva come JPEG
Nome #
ALPHA-TOCOPHEROL SUCCINATE INHIBITS NF-KAPPA-B NUCLEAR TRANSLOCATION VIA NRF2 ACTIVATION THUS INDUCING A DETOXIFICATION RESPONSE AGAINST PRO-OXIDANT REDOX-CYCLING COMPOUNDS 82
Denervation does not Induce Muscle Atrophy Through Oxidative Stress 62
Cyclo(His-Pro) inhibits NLRP3 inflammasome cascade in ALS microglial cells 62
Acetamidine-based iNOS inhibitors as molecular tools to counteract inflammation in BV2 microglial cells 62
Adenosine A1 receptors contribute to mitochondrial vulnerability to pro-oxidant stressors 61
Inhibition of NF-κB nuclear translocation via HO-1 activation underlies α-tocopheryl succinate toxicity 60
Potential influence of cyclo(His-pro) on proteostasis: Impact on neurodegenerative diseases 60
Furanodien-6-one from Commiphora erythraea inhibits the NF-κB signalling and attenuates LPS-induced neuroinflammation 56
A(1) and A(3) adenosine receptors alter glutathione status in an organ-specific manner and influence the changes after inhibition of gamma-glutamylcysteine ligase. 55
Cyclo(His-Pro) exerts anti-inflammatory effects by modulating NF-κB and Nrf2 signalling. 53
Peroxynitrite Activates the NLRP3 Inflammasome Cascade in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis 53
Cyclo(His-Pro) promotes cytoprotection by activating Nrf2-mediated up regulation of antioxidant defence. 51
2-Cl-adenosine: an antimetabolite in human prostate cancer PC3 cells. 49
Focus on cyclo(His-Pro): history and perspectives as antioxidant peptide. 46
Cycloserine enantiomers are reversible inhibitors of human alanine:glyoxylate aminotransferase: Implications for Primary Hyperoxaluria type 1 46
MITOCHONDRIAL EXPRESSION OF A1 ADENOSINE RECEPTOR EXACERBATES PRO-OXIDANT INJURY 44
α-Tocopheryl succinate pre-treatment attenuates quinone toxicity in prostate cancer PC3 cells. 44
Cyclo (His-Pro) Protects SOD1G93A Microglial Cells from Paraquat Induced Toxicity 44
Molecular events underlying antioxidant properties of cyclo(His-Pro) in PC12 cells 42
Cyclo(His-Pro) promotes cytoprotection by activating Nrf2-mediated up-regulation of antioxidant defence 41
ROS-independent Nrf2 activation in prostate cancer 40
Cyclo(His-Pro) alleviates LPS-induced neuroinflammation 38
Up-regulation of antioxidant defence by cyclo(His-Pro) through Nrf2 activation 37
Neuroinflammation and endoplasmic reticulum stress are coregulated by cyclo(His-Pro) to prevent LPS neurotoxicity 34
The role of cyclo(His-Pro) in neurodegeneration 34
Insight into the specificity and severity of pathogenic mechanisms associated with missense mutations through experimental and structural perturbation analyses 30
Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach 29
Molecular and Cellular Studies Reveal Folding Defects of Human Ornithine Aminotransferase Variants Associated With Gyrate Atrophy of the Choroid and Retina 26
Phosphoproteomic analysis of the effect of cyclo-(His-Pro)dipeptide on PC12 cells 25
Molecular and cellular basis of ornithine δ-aminotransferase deficiency caused by the V332M mutation associated with gyrate atrophy of the choroid and retina 24
Dimerization drives proper folding of human alanine:Glyoxylate aminotransferase but is dispensable for peroxisomal targeting 23
A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase 14
Identification of Human Alanine-Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1 13
CRISPR/Cas9-mediated knock-out of AGXT1 in HepG2 cells as a new in vitro model of Primary Hyperoxaluria Type 1 13
Structural dynamics shape the fitness window of alanine:glyoxylate aminotransferase 12
Erratum: Cyclo(His-Pro) up-regulates heme oxygenase 1 via activation of Nrf2-ARE signaling (Journal of Neurochemistry (2009) 111 (956-966)) 8
Impact of Enniatin and Deoxynivalenol Co-Occurrence on Plant, Microbial, Insect, Animal and Human Systems: Current Knowledge and Future Perspectives 8
Totale 1.481
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.825
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.825
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201911 0 0 0 0 0 0 0 0 0 0 11 0
2019/202088 0 1 11 0 13 3 14 1 19 17 5 4
2020/2021231 3 17 2 13 77 9 12 2 19 1 15 61
2021/2022296 10 39 6 3 14 8 9 83 19 28 33 44
2022/2023581 32 101 9 45 55 58 0 25 220 5 22 9
2023/2024147 22 23 12 3 1 1 44 10 24 7 0 0
Totale 1.481